全文获取类型
收费全文 | 5137篇 |
免费 | 311篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 139篇 |
妇产科学 | 276篇 |
基础医学 | 540篇 |
口腔科学 | 80篇 |
临床医学 | 706篇 |
内科学 | 931篇 |
皮肤病学 | 66篇 |
神经病学 | 505篇 |
特种医学 | 115篇 |
外科学 | 515篇 |
综合类 | 49篇 |
一般理论 | 6篇 |
预防医学 | 610篇 |
眼科学 | 72篇 |
药学 | 339篇 |
中国医学 | 4篇 |
肿瘤学 | 431篇 |
出版年
2023年 | 32篇 |
2022年 | 36篇 |
2021年 | 138篇 |
2020年 | 82篇 |
2019年 | 91篇 |
2018年 | 134篇 |
2017年 | 93篇 |
2016年 | 99篇 |
2015年 | 81篇 |
2014年 | 146篇 |
2013年 | 239篇 |
2012年 | 358篇 |
2011年 | 383篇 |
2010年 | 190篇 |
2009年 | 181篇 |
2008年 | 311篇 |
2007年 | 294篇 |
2006年 | 292篇 |
2005年 | 267篇 |
2004年 | 267篇 |
2003年 | 261篇 |
2002年 | 233篇 |
2001年 | 83篇 |
2000年 | 72篇 |
1999年 | 68篇 |
1998年 | 65篇 |
1997年 | 79篇 |
1996年 | 81篇 |
1995年 | 57篇 |
1994年 | 38篇 |
1993年 | 30篇 |
1992年 | 66篇 |
1991年 | 56篇 |
1990年 | 46篇 |
1989年 | 46篇 |
1988年 | 29篇 |
1987年 | 48篇 |
1986年 | 45篇 |
1985年 | 39篇 |
1984年 | 45篇 |
1983年 | 24篇 |
1982年 | 16篇 |
1981年 | 22篇 |
1980年 | 19篇 |
1979年 | 27篇 |
1978年 | 18篇 |
1977年 | 26篇 |
1976年 | 12篇 |
1975年 | 15篇 |
1974年 | 13篇 |
排序方式: 共有5466条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
Participation in pediatric oncology research protocols: Racial/ethnic,language and age‐based disparities 下载免费PDF全文
95.
Isochromosomes in childhood acute lymphoblastic leukemia: a collaborative study of 83 cases. 总被引:2,自引:0,他引:2
C H Pui A J Carroll S C Raimondi M J Schell D R Head J J Shuster W M Crist M J Borowitz M P Link F G Behm 《Blood》1992,79(9):2384-2391
Cytogenetic analysis of leukemic cells from 2,805 children with newly diagnosed acute lymphoblastic leukemia (ALL) identified 83 cases (3%) that had a stemline with at least one isochromosome. The i(9q) was present in 28 (1%), the i(17q) in 23 (0.8%), and the i(7q) in 23 (0.8%). Other isochromosomes--i(21q), i(6p), i(1q), i(8q), or i(Xq)--were found in only 12 cases (0.4%). The isochromosome cases were more likely than were other ALL cases to have a pre-B immunophenotype (38% v 25%, P = .02) and leukemic cell hyperdiploidy greater than 50 (37% v 24%, P = .02); five cases had both features. The i(9q) was associated with age greater than 10 years (P less than .05) and the pre-B immunophenotype (P = .05); both the i(17q) and i(7q) had high frequencies of hyperdiploidy greater than 50 (P less than .0001 and P = .05, respectively). The t(1;19)(q23;p13) was a common feature (23%) in cases with the i(9q), i(7q), i(6p), or i(1q). These findings establish the i(9q), i(17q), and i(7q) as nonrandom chromosomal abnormalities in ALL. The prognostic significance of the presence of isochromosome(s) remains to be determined. 相似文献
96.
97.
98.
Aromatase-deficient (ArKO) mice are deficient in estrogens due to deletion of the aromatase gene. We hypothesized that there may be changes in the cardiovascular system of ArKO mice because of evidence linking estrogens with improved cardiovascular outcomes and the induction of the glucocorticoid-metabolizing enzyme, 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2), gene in the kidney, which is important for the regulation of blood pressure (BP). BP and baroreflex sensitivity (BRS) in female conscious ArKO mice were compared with those in age- and weight-matched wild-type (WT) mice. Power spectral analysis was used to determine cardiovascular variability and BRS. Although systolic BP was similar in the two groups, diastolic and mean BPs were lower in the ArKO mice (-6.3 +/- 1.9 and -4.6 +/- 2.1 mm Hg, respectively). Heart rate (HR) was greater in the ArKO mice (+36 +/- 6 beats/min). The mean BP in WT mice was 105 mm Hg, and the HR was 481 beats/min. In the autonomic frequency range, BP variability was 74% greater, and HR variability was only 26% that in WT mice. The BRS of ArKO mice was 46% of the value observed in WT mice. 11betaHSD2 levels were unaltered in ArKO mice, except in the kidney, where they were only 10% of WT levels. Estradiol administration to ArKO mice restored renal 11betaHSD2 to WT levels. The results show that ArKO mice have lower diastolic BP, but increased BP variability, perhaps due to an impaired BRS. Thus, aromatase activity is critical for normal autonomic control of the heart and, hence, for reducing the deleterious effects of high BP variability. 相似文献
99.
Erika Assarsson Jason A. Greenbaum Magnus Sundstr?m Lana Schaffer Jennifer A. Hammond Valerie Pasquetto Carla Oseroff R. Curtis Hendrickson Elliot J. Lefkowitz David C. Tscharke John Sidney Howard Grey Steven R. Head Bjoern Peters Alessandro Sette 《Proceedings of the National Academy of Sciences of the United States of America》2008,105(40):E63-E64
100.
Inhibition of glycogen synthase kinase (GSK)-3 reduces ischemia/reperfusion injury by mechanisms that involve the mitochondria. The goal of this study was to explore possible molecular targets and mechanistic basis of this cardioprotective effect. In perfused rat hearts, treatment with GSK inhibitors before ischemia significantly improved recovery of function. To assess the effect of GSK inhibitors on mitochondrial function under ischemic conditions, mitochondria were isolated from rat hearts perfused with GSK inhibitors and were treated with uncoupler or cyanide or were made anoxic. GSK inhibition slowed ATP consumption under these conditions, which could be attributable to inhibition of ATP entry into the mitochondria through the voltage-dependent anion channel (VDAC) and/or adenine nucleotide transporter (ANT) or to inhibition of the F(1)F(0)-ATPase. To determine the site of the inhibitory effect on ATP consumption, we measured the conversion of ADP to AMP by adenylate kinase located in the intermembrane space. This assay requires adenine nucleotide transport across the outer but not the inner mitochondrial membrane, and we found that GSK inhibitors slow AMP production similar to their effect on ATP consumption. This suggests that GSK inhibitors are acting on outer mitochondrial membrane transport. In sonicated mitochondria, GSK inhibition had no effect on ATP consumption or AMP production. In intact mitochondria, cyclosporin A had no effect, indicating that ATP consumption is not caused by opening of the mitochondrial permeability transition pore. Because GSK is a kinase, we assessed whether protein phosphorylation might be involved. Therefore, we performed Western blot and 1D/2D gel phosphorylation site analysis using phos-tag staining to indicate proteins that had decreased phosphorylation in hearts treated with GSK inhibitors. Liquid chromatographic-mass spectrometric analysis revealed 1 of these proteins to be VDAC2. Taken together, we found that GSK-mediated signaling modulates transport through the outer membrane of the mitochondria. Both proteomics and adenine nucleotide transport data suggest that GSK regulates VDAC and that VDAC may be an important regulatory site in ischemia/reperfusion injury. 相似文献